Adolor Faces R&D Setbacks, One With Entereg
This article was originally published in The Pink Sheet Daily
Executive Summary
Adolor discontinues development of alvimopan to treat chronic opioid bowel dysfunction after unsuccessful partnering discussions; it will proceed with the preclinical compound ADL7445.